US20190381115A1 - Faecalibacterium prausnitzii strains for treating and preventing gastrointestinal pain - Google Patents

Faecalibacterium prausnitzii strains for treating and preventing gastrointestinal pain Download PDF

Info

Publication number
US20190381115A1
US20190381115A1 US15/524,808 US201515524808A US2019381115A1 US 20190381115 A1 US20190381115 A1 US 20190381115A1 US 201515524808 A US201515524808 A US 201515524808A US 2019381115 A1 US2019381115 A1 US 2019381115A1
Authority
US
United States
Prior art keywords
bacterial strain
composition
faecalibacterium prausnitzii
prausnitzii
bacterial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/524,808
Other languages
English (en)
Inventor
Philippe Langella
Sylvie MIQUEL
Rebeca Martin Rosique
Luis Bermudez Humaran
Muriel Thomas
Harry SOKOL
Frédéric CARVALHO
Vassilia Theodorou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ecole D'ingenieurs De Purpan
Universite Pierre et Marie Curie Paris 6
Assistance Publique Hopitaux de Paris APHP
Institut National de la Sante et de la Recherche Medicale INSERM
Institut National de Recherche pour lAgriculture lAlimentation et lEnvironnement
Original Assignee
Ecole D'ingenieurs De Purpan
Universite Pierre et Marie Curie Paris 6
Assistance Publique Hopitaux de Paris APHP
Institut National de la Recherche Agronomique INRA
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ecole D'ingenieurs De Purpan, Universite Pierre et Marie Curie Paris 6, Assistance Publique Hopitaux de Paris APHP, Institut National de la Recherche Agronomique INRA, Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Ecole D'ingenieurs De Purpan
Assigned to ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (APHP), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), ECOLE D'INGENIEURS DE PURPAN, UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6), INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (INRA) reassignment ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (APHP) ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CARVALHO, FREDERIC, THEODOROU, VASSILIA, BERMUDEZ HUMARAN, Luis, LANGELLA, PHILIPPE, MARTIN ROSIQUE, Rebeca, SOKOL, Harry, THOMAS, MURIEL, MIQUEL, Sylvie
Publication of US20190381115A1 publication Critical patent/US20190381115A1/en
Assigned to INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT (INRAE) reassignment INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT (INRAE) CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (INRA)
Assigned to INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT reassignment INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY DATA PREVIOUSLY RECORDED ON REEL 052469 FRAME 0167. ASSIGNOR(S) HEREBY CONFIRMS THE CHANGE OF NAME. Assignors: INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (INRA)
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales

Definitions

  • the present invention concerns Faecalibacterium prausnitzii strains for use in the treatment and prevention of visceral abdominal pain in an individual, in particular of gastrointestinal pain of non-inflammatory origin.
  • the present invention also concerns a composition, in particular an oral composition, comprising specific Faecalibacterium prausnitzii strains as well as new Faecalibacterium prausnitzii strains per se.
  • Visceral abdominal pain and in particular gastrointestinal pain, is a very common disorder that affects millions of people every year all over the world and is a leading cause of patient visits to clinics. Abdominal pain is present on questioning of 75 percent of otherwise healthy adolescent students (Hyams et al. J. Pediatr. 1996; 129:220) and in about half of all adults (Heading; Scand J Gastroenterol Suppl. 1999; 231:3).
  • Such visceral pain can originate from various origins such as peptic disease, pancreatitis in alcoholics, inflammatory bowel disease, appendicitis, ruptured viscus, acute volvulus or even gastritis, biliary colic, gastroenteritis, splenic rupture, hepatic laceration or small bowel rupture.
  • gastrointestinal disorders in particular non-inflammatory gastrointestinal disorders, and more particularly Irritable Bowel Syndrome (IBS), are the most frequent reasons for visceral abdominal pain in an individual.
  • IBS Irritable Bowel Syndrome
  • IBS is one of the 25 most wide-spread recognized pathologies of the gastrointestinal tract. In the USA and in the first five European countries (France, Germany, the United Kingdom, Spain and Italy), in 2009, IBS affected more than 24 million persons. IBS accounts for 40 to 60% of referrals to gastroenterology outpatient clinics (Jones et al., Gut 2000; 47(Suppl 2): ii1-ii19).
  • IBS insulin-predominant
  • c-IBS constipation-predominant
  • d-IBS diarrhea-predominant
  • a-IBS alternating between 25 the two
  • IBS The pathophysiology of IBS is believed to involve alterations in the brain-gut axis. However, the mechanisms by which these changes lead to IBS remain poorly understood.
  • IBS is in particular characterized by a colonic hypersensitivity. This pain sensitivity is usually studied using variation of balloon distention in the rectum, a procedure in which a balloon is inserted into the rectum and slowly inflated. This common complaint is a crucial feature because of its significant impact on a patient's quality of life and lack of efficient therapies.
  • IBS Irritable Bowel Syndrome
  • the present invention aims to provide novel substances, in particular probiotics, and compositions for treating and/or preventing visceral abdominal pain in an individual, more particularly gastrointestinal pain of non-inflammatory origin.
  • Faecalibacterium prausnitzii F. prausnitzii
  • F. prausnitzii Faecalibacterium prausnitzii
  • the inventors have demonstrated that F. prausnitzii strains outside of these phylogroups, such as the strain CNCM I-4541, do not possess such advantageous properties.
  • NMS Neonatal Maternal Separation
  • CHS colonic hypersensitivity
  • PRS Partial Restraint Stress
  • Strains according to the invention are more particularly able to diminish the sensitivity of nociceptors in the gastrointestinal tract of an individual and consequently to prevent and/or reduce colonic hypersensitivity of said individual.
  • the present invention relates to a bacterial strain of the Faecalibacterium prausnitzii species selected from a bacterial strain belonging to one of the phylogroups I, II and III according to the invention, for use in the treatment and/or prevention of visceral abdominal pain in an individual.
  • strains identified by the inventors are thus probiotics that can be used for the above-indicated purposes.
  • An individual according to the invention is a mammal, in particular a human.
  • Visceral abdominal pain is pain associated with organs of the abdomen of the individual.
  • the visceral abdominal pain is in particular a gastrointestinal pain, in particular a colonic pain.
  • a bacterial strain of the Faecalibacterium prausnitzii species according to the invention is different from the strain A2-165.
  • bacterial strains according to the invention for use as indicated here above are selected from the group consisting of bacterial strains deposited to the CNCM under the accession numbers I-4542, I-4544, I-4540, I-4574, I-4543, I-4575, I-4573, I-4644 and I-4546, and in particular the bacterial strain deposited to the CNCM under the accession number I-4573.
  • the visceral pain according to the invention is caused by a gastrointestinal disorder, in particular a non-inflammatory gastrointestinal disorder.
  • a gastrointestinal disorder of the invention in particular according to this embodiment, can be a gastrointestinal hypersensitivity, in particular a colonic hypersensitivity, and is preferably an Irritable Bowel Syndrome, in particular an alternating-type Irritable Bowel Syndrome.
  • such gastrointestinal disorder according to the invention can be selected from the group consisting of IBS and constipation.
  • a bacterial strain for use according to the invention is comprised in a composition comprising a physiologically acceptable medium, preferably in an oral composition, and most preferably in a food supplement.
  • the present invention relates to a composition
  • a composition comprising, in a physiologically acceptable medium, at least one bacterial strain of Faecalibacterium prausnitzii selected from the group consisting of bacterial strains deposited to the CNCM under the accession numbers I-4542, I-4544, I-4540, I-4574, I-4543, I-4575, I-4573, I-4644 and I-4546.
  • said bacterial strain of the Faecalibacterium prausnitzii species is the bacterial strain deposited to the CNCM under the accession numbers I-4573.
  • physiologically acceptable medium is understood to mean a medium that is compatible with the organism of the individual to whom said composition is intended to be administered. It can for example be any non-toxic solvent such as water. In particular, said medium is compatible with an oral administration.
  • a composition of the invention is preferably for the oral route and in particular in the form of a food supplement.
  • a composition of the invention for the oral route can be selected from the group consisting of a food product, a drink, a pharmaceutical, a nutraceutical, a food additive, a food supplement and a dairy product. It can in particular be a food supplement.
  • the inventors have also indentified new Faecalibacterium prausnitzii strains having the specific abilities discussed previously.
  • a further object of the invention consists in an isolated bacterial strain selected from the group consisting of bacterial strains deposited to the CNCM under the accession numbers I-4542, I-4544, I-4540, I-4574, I-4543, I-4575, I-4573, I-4644 and I-4546.
  • said bacterial strain is the bacterial strain deposited to the CNCM under the accession number I-4573.
  • a Faecalibacterium prausnitzii strain of the invention has no negative impact in an individual not suffering from visceral abdominal pain according to the invention and is thus perfectly safe for use.
  • FIG. 1A illustrates the variation of the Vicero Motrice Response (VMR—mV/s) of a colon depending on the Distension volume (4) of a balloon inserted into the rectum and slowly inflated, in non-handled (NH) (normal lines) or Maternal separated (MS) (bold lines) mice pre-treated with PBS (dotted lines) or with CNCM I-4573 (full lines) bacteria according to the invention.
  • VMR Vicero Motrice Response
  • FIG. 1B illustrates the variation of the Vicero Motrice Response (VMR—mV/s) of a colon depending on the Distension volume (tt) of a balloon inserted into the rectum and slowly inflated, in non-handled (NH) (normal lines) or Maternal separated (MS) (bold lines) mice pre-treated with PBS (dotted lines) or with CNCM I-4541 (full lines) bacteria outside of the invention.
  • VMR Vicero Motrice Response
  • FIG. 2 illustrates 35 Faecalibacterium prausnitzii strains and their distribution in or outside of the three phylogroups of the invention.
  • Faecalibacterium prausnitzii strains CNCM I-4541 (SEQ ID No: 16) and 513E3 (SEQ ID No: 17) are outside the three phylogroups of the invention. The method for obtaining said distribution is discussed further below.
  • PRS-4573 continuous slashed line
  • the present inventors have performed a huge amount of work with the view of identifying the ability of specific Faecalibacterium prausnitzii strains to treat and/or prevent visceral abdominal pain, and in particular gastrointestinal pain, in an individual.
  • Faecalibacterium prausnitzii strains belonging to three phylogroups defined further exhibit the ability to diminish the sensitivity of nociceptors in the gastrointestinal tract of an individual.
  • the bacterial strains according to the invention can prevent and/or reduce visceral abdominal pain, in particular gastrointestinal pain, in an individual, in particular in an individual suffering from a gastrointestinal non-inflammatory disorder, and in particular from a colonic hypersensitivity, such as in IBS.
  • bacterial strains of the invention are in particular able to reduce the Vicero Motrice Response (VMR) of a colon when a balloon inserted into the rectum is slowly inflated in an IBS mouse model pre-treated with a bacterial strain of the invention. Said VMR is brought back to a normal intensity, since the VMR level observed after administration of a strain according to the invention is similar to the VMR observed in mice not suffering from colonic hypersensitivity.
  • VMR Vicero Motrice Response
  • F. prausnitzii is a major member of the Firmicutes phylum and is part of the most abundant commensal bacteria in the healthy human large intestine microbiota.
  • F. prausnitzii is an extremely oxygen sensitive (EOS) bacterium and is thus difficult to cultivate, even in anaerobic conditions (Duncan et al. 2002, Int. J. Syst. Evol. Microbiol. 52(Pt 6): 2141-6 and Lopez-Siles et al. Appl. Environ Microbiol. 2012 January;78(2):420-8).
  • EOS extremely oxygen sensitive
  • prausnitzii is in particular known as being one of the most abundant butyrate-producing bacterium in the human gastrointestinal tract, the short chain fatty acid butyrate being very important in gut physiology, systemic functions and beneficial effects for human health (Macfarlane and Macfarlane (2011), J. Clin. Gastroenterol. 45 Suppl: S120-7).
  • F. prausnitzii is also known for having anti-inflammatory and protective effects in murine models of acute and chronic colitis, i.e. in inflammatory disorders (Martin et al., Inflamm Bowel Dis. 2014 March; 20(3):417-30 and Sokol et al., Proc Natl Acad Sci USA. 2008 Oct. 28;105(43):16731-6).
  • the ability of the F. prausnitzii strains of the invention to prevent visceral abdominal pain, and in particular gastrointestinal pain, in an individual is specific to the strains identified by the inventors, and constituting the three phylogroups of the invention.
  • Such specific antinociceptive activity is illustrated in the examples, wherein a comparative test has been performed with a F. prausnitzii strain not part of the three phylogroups of the invention, i.e. the strain CNCM I-4541. As demonstrated in these examples, this strain does not possess the antinociceptive activity of the strains of the invention.
  • Isolated Faecalibacterium prausnitzii strains have been classified by the inventors in three phylogroups illustrated in FIG. 2 according to 16S rRNA sequences.
  • 16S rRNA sequences were amplified and PCR products purified with the Wizard SV Gel. PCR Clean-Up system (Promega) was used to obtain bidirectional partial 16S rRNA gene sequences by using primers. All DNA sequences were confirmed by sequencing (Eurofins MWG Operon, Ebersberg, Germany).
  • the percentage of replicate trees in which the associated taxa clustered together in the bootstrap test (500 replicates) are shown next to the branches (Zharkikh A. and Li WH, Mol Phylogenet Evol. 1995; 4:44-63).
  • the tree is drawn to scale, with branch lengths in the same units as those of the evolutionary distances used to infer the phylogenetic tree.
  • the evolutionary distances were computed using the Maximum Composite Likelihood method (Tamura et al., Proc Natl Acad Sci USA. 2004; 101:11030-11035) and are in the units of the number of base substitutions per site.
  • Eubacterium desmolans was used to root the tree (SEQ ID No: 18).
  • SEQ ID No: 18 In sequence SEQ ID No: 18, ‘n’ is used to represent any ambiguous nucleotides.
  • a bacterial strain of the invention is selected from phylogroup I.
  • Bacterial strains belonging to phylogroup I can be represented by the strains consisting of:
  • a bacterial strain belonging to phylogroup I is selected from the group consisting of bacterial strains deposited to the CNCM under the accession numbers I-4542, I-4544 and I-4540.
  • a bacterial strain of the invention is selected from phylogroup II.
  • Bacterial strains belonging to phylogroup I1 can for example be selected from the group consisting of bacterial strains of reference HTF-60C, HTF-I, HTF-E, HTF-C, HTF-A, HTF-B and HTF-F.
  • a bacterial strain of the invention is selected from phylogroup III.
  • Bacterial strains belonging to phylogroup III can be represented by the strains consisting of:
  • a bacterial strain belonging to phylogroup III is selected from the group consisting of bacterial strains deposited to the CNCM under the accession numbers I-4574, I-4543, I-4575, I-4573, I-4644 and I-4546.
  • Bacterial strains of reference ATCC 27768, A2-165, L2-15, L2-39, L2-6, L2-61, M21/2, S3L/3, S4L/4, HTF-A, HTF-B, HTF-C, HTF-E, HTF-F, HTF-I, HTF-60C and HTF-75H can be obtained as indicated in Lopez-Siles et al., Appl. Environ. Microbiol. 2012, 78(2):420.
  • a bacterial strain of the invention is selected from phylogroups I and/or III. More particularly, a bacterial strain of the invention is selected from phylogroups I and/or III with the proviso that the bacterial strain is different from the bacterial strain A2-165.
  • a bacterial strain of the invention is selected from the group consisting of bacterial strains deposited to the CNCM under the accession numbers I-4542, I-4544, I-4540, I-4574, I-4543, I-4575, I-4573, I-4644 and I-4546.
  • a bacterial strain of the invention is preferably the bacterial strain deposited to the CNCM under the accession number I-4573.
  • the inventors have also indentified new Faecalibacterium prausnitzii strains having the specific abilities discussed previously.
  • the present invention further concerns an isolated bacterial strain selected from the group consisting of bacterial strains deposited to the CNCM under the accession numbers I-4542, I-4544, I-4540, I-4574, I-4543, I-4575, I-4573, I-4644 and I-4546.
  • Said bacterial strain is in particular the bacterial strain deposited to the CNCM under the accession number I-4573.
  • a suitable daily dose of a bacterial strain according to the invention is from 10 3 to 10 12 colony forming units (cfu), more preferably from 10 7 to 10 11 cfu as a medicament, for example as a daily dose equivalent to 10 10 cfu.
  • a Faecalibacterium prausnitzii strain of the invention is for use in the treatment and/or prevention of visceral abdominal pain in an individual.
  • the strains of the invention are probiotics whose activity lies in the gut.
  • a probiotic bacterium according to the invention denotes a bacterium which ingested live in adequate quantities can exert beneficial effects on the human health.
  • the bacteria strains of the invention can be administered to the gut of an individual to be treated by different ways, i.e. by the oral, rectal or parenteral route.
  • a bacterium according to the invention is preferably administered by the oral or rectal route, more preferably by the oral route.
  • a bacterial strain of the invention is comprised in a composition comprising a physiologically acceptable medium.
  • a composition comprising a physiologically acceptable medium.
  • Such composition is preferably for the oral route, and in particular in the form of a food supplement.
  • the present invention further concerns a composition
  • a composition comprising, in a physiologically acceptable medium, at least one bacterial strain of Faecalibacterium prausnitzii of the invention.
  • the present invention relates to a composition
  • a composition comprising, in a physiologically acceptable medium, at least one bacterial strain of Faecalibacterium prausnitzii selected from the group consisting of bacterial strains deposited to the CNCM under the accession numbers I-4542, I-4544, I-4540, I-4574, I-4543, I-4575, I-4573, I-4644 and I-4546.
  • composition according to the invention comprises at least one bacterial strain deposited to the CNCM under the accession number I-4573.
  • a composition according to the invention is intended for the gastrointestinal tract, in particular the gut.
  • composition according to the invention is selected from an oral, rectal or parenteral composition.
  • a composition of the invention is preferably an oral or rectal composition, more preferably an oral composition.
  • a composition of the invention is an oral composition, i.e. is intended for oral administration to a subject.
  • composition can be in the form of a suspension, tablet, pill, capsule, granulate or powder.
  • composition according to the invention for the oral route can be selected from the group consisting of a food product, a drink, a pharmaceutical, a nutraceutical, a food additive, a food supplement or a dairy product, and is in particular a food supplement.
  • a composition according to the invention is a food supplement.
  • Food supplement for oral administration may be present in capsules, gelatin capsules, soft capsules, tablets, sugar-coated tablets, pills, pastes, pastilles, gums, drinkable solutions or emulsions, a syrup or a gel.
  • a composition according to the invention intended for oral administration, can be provided with a coating resistant to gastric juice, so as to ensure that the bacterial strain of the invention comprised in said composition can pass through the stomach undamaged. The release of the bacterial strain can thus takes place for the first time in the upper intestinal tract.
  • a food supplement according to the invention can also include a sweetener, a stabilizer, an antioxidant, an additive, a flavouring agent and/or a colorant.
  • the formulation thereof is carried out by means of the usual methods for producing sugar-coated tablets, gel capsules, gels, hydrogels for controlled release, emulsions, tablets or capsules.
  • a composition according to the invention can also be in the form of a nutritional composition.
  • a nutritional composition according to the invention is in the form of a yogurt, a cereal bar, a breakfast cereal, a dessert, a frozen food, a soup, a pet food, a liquid suspension, a powder, a tablet, a gum or a candy.
  • composition containing a bacterial strain of the invention is administered intrarectally.
  • a rectal administration preferably takes place in the form of a suppository, enema or foam.
  • a composition according to the invention contains an amount of bacterial strains of the invention equivalent to between 10 3 and 10 12 cfu/g (dry weight basis), more preferably between 10 6 and 10 9 cfu/g.
  • a composition according to the invention can further comprise at least one of: antioxidants, fish oils, DHA, EPA, vitamins, minerals, phytonutrients, protein, fat, probiotics, and combinations thereof.
  • the present invention further concerns the use of at least one bacterial strain of the Faecalibacterium prausnitzii species selected from a bacterial strain belonging to at least one of the phylogroups I, II and III, for the treatment and/or prevention of visceral abdominal pain in an individual.
  • the present invention also concerns the use of a composition, preferably an oral composition, comprising, in a physiologically acceptable medium, at least one bacterial strain of the Faecalibacterium prausnitzii species selected from a bacterial strain belonging to at least one of the phylogroups I, II and III, for the treatment and/or prevention of visceral abdominal pain in an individual.
  • a composition preferably an oral composition, comprising, in a physiologically acceptable medium, at least one bacterial strain of the Faecalibacterium prausnitzii species selected from a bacterial strain belonging to at least one of the phylogroups I, II and III, for the treatment and/or prevention of visceral abdominal pain in an individual.
  • F. prausnitzii strains according to the invention have been tested for their ability to have a direct impact on visceral pain, and more particularly on colonic hypersensitivity.
  • the F. prausnitzii strains isolates used in the present example all are of human fecal origin from healthy patients. Said isolates were obtained from the highest countable dilution of human fecal samples in roll tubes of anaerobic M2GSC medium as discussed in Lopez-Sites et al. (Appl. Environ Microbiol. 2012; 78:420-428).
  • NMS Neonatal Maternal Separation
  • CHS colonic hypersensitivity
  • mice After birth, wild-type C57Bl/6J were isolated from their mother from D2 to D14, three hours a day, from 9 a.m. to 12 a.m. At nine-week old age, male mice were orally treated each day for nine days with 200 ⁇ L of 10 ⁇ 10 10 CFU/mL of:
  • VMR Vicero Motrice Response
  • colonic sensitivity was assessed by quantifying visceromotor response with abdominal electromyography (EMG) recordings in response to colorectal distension.
  • the inventors also validated this model as being non-inflammatory by checking the cytokines pattern by measurement of 13 types of cytokines in serum samples of stressed (MS: Maternal separated) and non-stressed (NH: Non-handled) mice.
  • NMS does not induce changes in colonic macroscopic damage, loss of architectural epithelium, goblet cell depletion, oedema/ulceration or inflammatory cell infiltrates.
  • NMS does not induce changes in body weight, colon weight and length and in spleen weight when stressed (MS) mice are compared to the control group (PBS).
  • control Maternal separated (MS) mice to whom only PBS was administered, present a high VMR, two times higher than the VMR of the non-handled (NH) mice, treated with CNCM I-4573 bacteria or only with PBS.
  • MS mice to whom CNCM I-4573 bacteria of the invention were administered possess a VMR statistically similar to the one of NH mice, all along the growth of the Volume Distension.
  • FIG. 1B there is no statistical difference between the results obtained with MS mice only treated with PBS or treated with CNCM I-4541 bacteria.
  • Electrodes were exteriorized at the neck level by a glass tube attached to the skin.
  • Rats colonic sensitivity induced by PRS was assessed by quantifying electrical response through an electroencephalograph Reega Mini-hui (ALVAR, France) and expressed as number of abdominal cramps for a five min period (as previously described in Eutamene, H. et al.; J. Physiol. 506 (Pt 1), 245-252 (1998)).
  • CRD was performed with an arterial embolectomy catheter (Fogarty; Edwards Laboratoire, Inc., Santa Ana, Calif., USA) introduced into the rectum (1 cm from the anus) and fixed at the base of the tail.
  • an arterial embolectomy catheter Fegarty; Edwards Laboratoire, Inc., Santa Ana, Calif., USA
  • Distension of the colon was performed by connecting the catheter to a syringe and consecutive injections of different volumes (0.4, 0.8, 1.2 ml) with an interval of 5 minutes.
  • a p value of less than 0.05 was considered significant.
  • PRS increased the number of abdominal cramps in response to CRD in a volume-dependent manner ( FIGS. 3A and 3B ).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
US15/524,808 2014-11-13 2015-11-13 Faecalibacterium prausnitzii strains for treating and preventing gastrointestinal pain Abandoned US20190381115A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14306803 2014-11-13
EP14306803.9 2014-11-13
PCT/EP2015/076572 WO2016075294A1 (en) 2014-11-13 2015-11-13 Faecalibacterium prausnitzii strains for treating and preventing gastrointestinal pain

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2015/076572 A-371-Of-International WO2016075294A1 (en) 2014-11-13 2015-11-13 Faecalibacterium prausnitzii strains for treating and preventing gastrointestinal pain

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/907,381 Division US11717543B2 (en) 2014-11-13 2020-06-22 Faecalibacterium prausnitzii strains for treating and preventing gastrointestinal pain

Publications (1)

Publication Number Publication Date
US20190381115A1 true US20190381115A1 (en) 2019-12-19

Family

ID=52000767

Family Applications (2)

Application Number Title Priority Date Filing Date
US15/524,808 Abandoned US20190381115A1 (en) 2014-11-13 2015-11-13 Faecalibacterium prausnitzii strains for treating and preventing gastrointestinal pain
US16/907,381 Active 2036-09-06 US11717543B2 (en) 2014-11-13 2020-06-22 Faecalibacterium prausnitzii strains for treating and preventing gastrointestinal pain

Family Applications After (1)

Application Number Title Priority Date Filing Date
US16/907,381 Active 2036-09-06 US11717543B2 (en) 2014-11-13 2020-06-22 Faecalibacterium prausnitzii strains for treating and preventing gastrointestinal pain

Country Status (10)

Country Link
US (2) US20190381115A1 (pl)
EP (1) EP3218524B1 (pl)
DK (1) DK3218524T3 (pl)
ES (1) ES2779409T3 (pl)
HU (1) HUE049340T2 (pl)
LT (1) LT3218524T (pl)
PL (1) PL3218524T3 (pl)
PT (1) PT3218524T (pl)
SI (1) SI3218524T1 (pl)
WO (1) WO2016075294A1 (pl)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022081428A1 (en) * 2020-10-16 2022-04-21 Nubiyota Llc Bacterial compositions and methods of use thereof for treatment of metabolic syndrome

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3046934B1 (fr) 2016-01-25 2018-01-26 Institut National De La Recherche Agronomique (Inra) Souche de faecalibacterium prausnitzii cncm i-4573 pour le traitement et la prevention d'une inflammation gastro-intestinale
WO2018027898A1 (zh) * 2016-08-12 2018-02-15 深圳华大基因研究院 一种产丁酸栖粪杆菌及其培养方法和应用
JP6862464B2 (ja) * 2016-09-06 2021-04-21 ビージーアイ シェンチェン フィーカリバクテリウム・ロンガム（Ｆａｅｃａｌｉｂａｃｔｅｒｉｕｍ ｌｏｎｇｕｍ）およびその使用
EP3378949A1 (en) * 2017-03-22 2018-09-26 Assistance Publique - Hôpitaux de Paris Method for determining the potential efficacy of anticancer treatment
JP2022528749A (ja) * 2019-03-28 2022-06-15 シージェイ バイオサイエンス， インク． フィーカリバクテリウム属微生物およびそれを含む抗癌組成物
EP3838276A1 (en) * 2019-12-17 2021-06-23 Exeliom Biosciences Association of faecalibacterium prausnitzii strain cncm i-4573 with pentasa® for the treatment and prevention of gastrointestinal inflammation
KR102169794B1 (ko) * 2020-06-24 2020-10-27 주식회사 엔테로바이옴 신규한 피칼리박테리움 프로스니치 균주 eb-fpdk11 및 그의 용도
KR102185828B1 (ko) * 2020-08-26 2020-12-03 주식회사 엔테로바이옴 피칼리박테리움 프로스니치 균주를 포함하는 아토피성 질환 예방 또는 치료용 약학적 조성물
WO2023036957A1 (fr) 2021-09-10 2023-03-16 Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement Utilisation de faecalibacterium pour traiter une infection par un virus respiratoire
EP4252764A1 (en) * 2022-04-01 2023-10-04 Greentech Parabacteroides distasonis strain isolated from human feces and applications thereof
EP4389134A1 (en) * 2022-12-20 2024-06-26 Exeliom Biosciences Faecalibacterium prausnitzii strain cncm i-4573 for the treatment and prevention of clostridioides difficile infection

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100247489A1 (en) * 2006-12-22 2010-09-30 Saur-Brosch Roland Use of a composition made of mineral nutrients and optionally acetogenic and/or butyrogenic bacteria in order to avoid or reduce the formation of gas in the large intestine of a mammal and the resulting abdominal problems

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015020819A2 (pt) * 2013-03-05 2017-07-18 Academisch Ziekenhuis Groningen uso de faecalibacterium prausnitzii htf-f (dsm 26943) para supressão de inflamação

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100247489A1 (en) * 2006-12-22 2010-09-30 Saur-Brosch Roland Use of a composition made of mineral nutrients and optionally acetogenic and/or butyrogenic bacteria in order to avoid or reduce the formation of gas in the large intestine of a mammal and the resulting abdominal problems

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022081428A1 (en) * 2020-10-16 2022-04-21 Nubiyota Llc Bacterial compositions and methods of use thereof for treatment of metabolic syndrome

Also Published As

Publication number Publication date
SI3218524T1 (sl) 2020-11-30
ES2779409T3 (es) 2020-08-17
WO2016075294A1 (en) 2016-05-19
US11717543B2 (en) 2023-08-08
DK3218524T3 (da) 2020-04-06
HUE049340T2 (hu) 2020-09-28
LT3218524T (lt) 2020-07-10
EP3218524B1 (en) 2020-01-08
PL3218524T3 (pl) 2020-11-30
EP3218524A1 (en) 2017-09-20
PT3218524T (pt) 2020-03-26
US20200316138A1 (en) 2020-10-08

Similar Documents

Publication Publication Date Title
US11717543B2 (en) Faecalibacterium prausnitzii strains for treating and preventing gastrointestinal pain
JP6935632B2 (ja) 胃腸炎の処置及び予防のためのフィーカリバクテリウム・プラウスニッツィｃｎｃｍ ｉ−４５７３株
Bausserman et al. The use of Lactobacillus GG in irritable bowel syndrome in children: a double-blind randomized control trial
US20140363409A1 (en) Lactobacillus Reuteri DSM 17938 for the Development of the Enteric Nervous System
CN115364113A (zh) 合成组合物以及用于治疗肠易激综合症的方法
Rincel et al. Maternal separation in rodents: a journey from gut to brain and nutritional perspectives
CN108348535B (zh) 用于调节脑功能和行为的合成组合物和方法
ES2855701T3 (es) Composiciones que comprenden cepas bacterianas
CN111683666A (zh) 预防或减少伤害感受的包含hmo的组合物
US20210268040A1 (en) Streptococcus thermophilus cnrz160 strain for the treatment and prevention of intestinal inflammation and associated disorders in an individual
EP3630138A1 (en) Compositions comprising bacterial strains
Yajima et al. Diversity of the intestinal microbiota differently affects non-neuronal and atropine-sensitive ileal contractile responses to short-chain fatty acids in mice
US20230355688A1 (en) Parabacteroides distasonis strains for use thereof in the treatment and prevention of gastrointestinal diseases and of disorders associated with gastrointestinal diseases
US11607433B2 (en) Composition for preventing, improving, or treating autism spectrum disorders including Agathobaculum sp. strain as active ingredient
US20240139213A1 (en) Vitamin d compounds and methods of using the same
US11052117B2 (en) Use of a sweet whey containing infant formula for promoting the postnatal neuronal development of the infant gastrointestinal tract, and the establishment of the intestinal functions that it controls
O'Connor Bugs, breathing and blood pressure: the microbiota-gut-brain axis in cardiorespiratory control
TW201333193A (zh) 用於發育腸神經系統之洛德乳桿菌(Lactobacillus reuteri)DSM 17938
KR20220118423A (ko) 박테리아 균주를 포함하는 조성물
CN117241809A (zh) 用于治疗肝性脑病的组合物和方法
KR20240038015A (ko) 신생아의 치료에서 락토바실러스 파라카세이 박테리아 균주의 용도

Legal Events

Date Code Title Description
AS Assignment

Owner name: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE M

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LANGELLA, PHILIPPE;MIQUEL, SYLVIE;MARTIN ROSIQUE, REBECA;AND OTHERS;SIGNING DATES FROM 20170720 TO 20170724;REEL/FRAME:043152/0073

Owner name: INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (INR

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LANGELLA, PHILIPPE;MIQUEL, SYLVIE;MARTIN ROSIQUE, REBECA;AND OTHERS;SIGNING DATES FROM 20170720 TO 20170724;REEL/FRAME:043152/0073

Owner name: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (APHP), FR

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LANGELLA, PHILIPPE;MIQUEL, SYLVIE;MARTIN ROSIQUE, REBECA;AND OTHERS;SIGNING DATES FROM 20170720 TO 20170724;REEL/FRAME:043152/0073

Owner name: ECOLE D'INGENIEURS DE PURPAN, FRANCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LANGELLA, PHILIPPE;MIQUEL, SYLVIE;MARTIN ROSIQUE, REBECA;AND OTHERS;SIGNING DATES FROM 20170720 TO 20170724;REEL/FRAME:043152/0073

Owner name: UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6), FRANCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LANGELLA, PHILIPPE;MIQUEL, SYLVIE;MARTIN ROSIQUE, REBECA;AND OTHERS;SIGNING DATES FROM 20170720 TO 20170724;REEL/FRAME:043152/0073

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

AS Assignment

Owner name: INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT (INRAE), FRANCE

Free format text: CHANGE OF NAME;ASSIGNOR:INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (INRA);REEL/FRAME:052469/0167

Effective date: 20191010

AS Assignment

Owner name: INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT, FRANCE

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY DATA PREVIOUSLY RECORDED ON REEL 052469 FRAME 0167. ASSIGNOR(S) HEREBY CONFIRMS THE CHANGE OF NAME;ASSIGNOR:INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (INRA);REEL/FRAME:052510/0160

Effective date: 20191010

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION